α-Alkylidene δ-lactones inhibit quorum sensing phenotypes in strain CV026 showing interaction with the CviR receptor
Disruption of bacterial quorum sensing (QS) is presented as a promising strategy to overcome clinically relevant and phytopathogenic bacteria. This work presents α-alkylidene δ-lactones as new chemical scaffolds that inhibit the biosynthesis of violacein in the biosensor strain Chromobacterium CV026...
Gespeichert in:
Veröffentlicht in: | RSC advances 2023-06, Vol.13 (26), p.1845-1857 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Disruption of bacterial quorum sensing (QS) is presented as a promising strategy to overcome clinically relevant and phytopathogenic bacteria. This work presents α-alkylidene δ-lactones as new chemical scaffolds that inhibit the biosynthesis of violacein in the biosensor strain
Chromobacterium
CV026. Three molecules displayed higher than 50% violacein reduction when tested at concentrations lower than 625 µM. The most active α-alkylidene δ-lactone inhibited the hydrolysis of chitin concomitantly with the inhibition of violacein production in CV026, suggesting the disruption of its QS machinery. Further, RT-qPCR and competition experiments showed this molecule to be a transcriptional inhibitor of the QS-regulated operon
vioABCDE
. Docking calculations suggested a good correlation between binding affinity energies and inhibition effects, with all molecules positioned within the CviR autoinducer-binding domain (AIBD). The most active lactone yielded the best binding affinity energy, most probably due to its unprecedented binding with the AIBD. Our results show α-alkylidene δ-lactones as promising chemical scaffolds for the development of new QS inhibitors affecting LuxR/LuxI-systems.
α-Alkylidene δ-lactones are novel modulators of QS at the transcriptional level in CV026. Blind docking calculations found the best inhibitor interacting with CViR AIBD by a molecular binding mechanism distinct from classic AHL-based inhibitors. |
---|---|
ISSN: | 2046-2069 |
DOI: | 10.1039/d3ra01975f |